Workflow
Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
BOLTBolt Biotherapeutics(BOLT) GlobeNewswire·2025-05-12 20:05

Core Insights - Bolt Biotherapeutics reported financial results for Q1 2025, highlighting advancements in their immunotherapy pipeline and a cash balance of 58milliontofundoperationsthroughmid−2026[1][4][10].BusinessUpdate−Thecompanyisadvancingitspipelineofnovelimmunotherapies,withpromisingearlyclinicaldataforBDC−3042presentedatAACR2025andtheopeningofenrollmentforBDC−4182[2][4].−BDC−3042,aproprietaryagonistantibodytargetingdectin−2,showedafavorablesafetyprofileandanti−tumoractivityinaPhase1studyforpatientswithmetastaticsolidtumors[5].−BDC−4182,targetingclaudin18.2,hasopenedforenrollmentanddemonstratedcompleteregressionsinpreclinicalmodels[5].FinancialPerformance−Collaborationrevenuedecreasedto58 million to fund operations through mid-2026 [1][4][10]. Business Update - The company is advancing its pipeline of novel immunotherapies, with promising early clinical data for BDC-3042 presented at AACR 2025 and the opening of enrollment for BDC-4182 [2][4]. - BDC-3042, a proprietary agonist antibody targeting dectin-2, showed a favorable safety profile and anti-tumor activity in a Phase 1 study for patients with metastatic solid tumors [5]. - BDC-4182, targeting claudin 18.2, has opened for enrollment and demonstrated complete regressions in preclinical models [5]. Financial Performance - Collaboration revenue decreased to 1.2 million in Q1 2025 from 5.3 million in Q1 2024, primarily due to the completion of performance obligations under a previous agreement [10]. - Research and Development (R&D) expenses were 9.5 million in Q1 2025, down from 16.5 million in Q1 2024, attributed to reduced clinical expenses and restructuring [10]. - General and Administrative (G&A) expenses also decreased to 3.8 million from 5.8millionyear−over−year[10].−ThenetlossforQ12025was5.8 million year-over-year [10]. - The net loss for Q1 2025 was 11.0 million, compared to a net loss of 10.8millioninQ12024[12].CashPosition−AsofMarch31,2025,thecompanyhadcash,cashequivalents,andmarketablesecuritiestotaling10.8 million in Q1 2024 [12]. Cash Position - As of March 31, 2025, the company had cash, cash equivalents, and marketable securities totaling 58 million, expected to support operations through mid-2026 [4][10].